Elite Pharmaceuticals, Inc. reported its third‑quarter fiscal 2026 results, posting consolidated revenue of $31.6 million for the three months ended December 31 2025, a 120 % year‑over‑year increase from $14.36 million in the same period a year earlier.
Operating income surged to $9.0 million, up 721 % from $1.1 million in Q3 FY2025, while net income swung to $18.6 million, turning a prior‑year loss into a substantial profit.
The revenue jump was largely driven by strong sales of the newly launched generic lisdexamfetamine (the generic version of Vyvanse®) and the long‑standing naltrexone product, together with continued growth in the company’s core controlled‑release generics portfolio. Cost efficiencies and a favorable product mix also contributed to the operating income expansion.
Elite’s cash and restricted cash balance rose to $21.6 million from $8.7 million a year earlier, supported by operating cash flow and the repayment of related‑party loans. The company remains exposed to customer concentration risk, with a single customer accounting for 64 % of revenue and 70 % of receivables for the nine months ended December 31 2025.
The company is also managing ongoing patent litigation over a proposed generic OxyContin, which could impact future product offerings.
A conference call to discuss the results and provide an update on recent business developments is scheduled for February 18 2026.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.